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Abstract
Neuroproteomics is a scientific field that aims to study all the proteins of the central
nervous system, their expression, function, and interactions. The central nervous sys‐
tem is intricate and heterogeneous, and the study of its proteome is consequently
complex, with many biological questions still requiring deep investigation. For this,
mass spectrometry approaches, most often coupled with liquid chromatography (LC-
MS), have been the number one choice in proteomics, and over the years it has added
many important findings to the field. At this point it is important that proteomics
turns to the quantitative expression of proteins instead of only identifying which pro‐
teins are present in a given sample, much because the most important alterations may
be slight alterations in the quantity of a protein in a given situation. Therefore, many
LC-MS quantitative approaches have been developed relying on the labeling of the
proteins or even by using label-free techniques.
In this chapter, a brief description of the principles and procedures of several
approaches used for relative and absolute, targeted and untargeted quantification of
proteins is presented, complemented with a literature revision of their application in
the neurosciences field.
Keywords: Neuroproteomics, LC-MS techniques, central nervous system, protein rel‐
ative quantification, protein absolute quantification
1. Introduction
Neuroproteomics is a field that aims to study all the proteins of the central nervous system
(CNS), as a whole or related to a specific condition (for example, disease, drug response, etc.).
CNS is very complex, presenting a high degree of heterogeneity at several levels, such as
distinct brain regions, cellular networks, and cell types [1], each one characterized by a different
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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proteome. Even slight perturbations of this structure can lead to CNS disorders, resulting in
alterations in the proteome of all CNS constituents or of specific cellular networks.
Large-scale initiatives have been performed to sequence human and other organism’s genomes
[2], as well as the analysis of gene expression of the distinct regions and cells of the brain.
However, although these studies have contributed with crucial information, the end-point of
gene transcription is the synthesis of proteins, the effector molecules. This way, the complex
and dynamic nature of the proteome has led to a paradigm shift in the neurosciences field,
changing from the focus in genomic information to the analysis of the protein’s expression
levels, by resorting to several approaches [3, 4].
Proteomics methodologies aim to analyze a large number of proteins within a certain set of
samples of an experiment [5], and the great development of this area may be attributed to the
technological advances in mass spectrometry (MS), optimization in sample preparation, and
computer sciences that are now able to deal with the large amount of information generated
by the MS-based technologies [6, 7].
These approaches can deliver different types of data, such as identification of the protein in a
sample at a given moment, expression levels of the proteins (quantitative proteomics),
identification and quantification of post-translational modifications (PTM), and protein
interactions (for example protein-protein interactions) [7].
Over the past years, MS-based proteomics approaches have been able to characterize proteins
in complex mixtures; nonetheless, these approaches have largely been qualitative, successfully
identifying a high amount of proteins from one sample but failing in quantifying the expression
levels of these [5]. However, it has been pressing to turn the proteomics field to quantitative
approaches, once most of the interesting biological alterations are slight differences in the
amount of a protein present in a given situation [8].
The main goal of quantitative proteomics, or quantitative neuroproteomics in particular, is to
measure the expression level of, theoretically, all the proteins in a given sample, preferably in
a highly reproducible manner [9]. This quantitative information can be acquired in two distinct
ways: absolute quantification, where the amount of the protein in the sample is calculated (for
instance, in terms of concentration or copy number per cell); or relative quantification, where
the amount of a given protein is expressed as a fold change for the same protein relative to
another condition [5, 7]. The approaches to obtain relative quantification may be untargeted,
where virtually all the proteins in the sample are quantified; or targeted where the quantifi‐
cation is obtained for a selected protein or a set of proteins. A brief summary of the most
important methodologies is outlined in Figure 1.
The classical approach to obtain relative quantifications of a proteome was to perform a bi-
dimensional electrophoresis (2DE-Isoelectric focusing followed by SDS-PAGE), where the
identification of the proteins was obtained by a MS analysis and the relative quantification by
measuring the staining density of matched gel spots [9]. Nonetheless, in this method, some
types of proteins are underrepresented, and although hundreds to a few thousands of proteins
may be detected, many proteins with lower abundance are very difficult to quantify. Also, the
analysis of many samples by this method is laborious and time consuming. [9]
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Figure 1. Diagram with brief description of the LC-MS proteomics techniques.
Therefore, over the years several methodologies were developed that support proteomic
expression level quantification, and although the most popular are the so-called labeled
approaches (which require the stable isotopic labeling of the samples prior to MS analysis),
the label-free approaches are now gaining increasing interest mostly due to higher accuracy
and sensitivity of MS instruments and improvement of the algorithms for data analysis [9].
In this chapter, a brief introduction to the different LC-MS quantitative approaches will be
performed, mainly focusing on the main principle and their major achievements. Special
attention will be given to the most commonly used methods in each category, and finally a
revision of the literature on proteomics using those approaches will be performed, and
whenever possible, examples in neuroproteomics field will be provided to elucidate the
concepts.
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2. Stable isotope labeling quantitative approaches
The major advantage of using MS to perform quantification instead of gel-based quantification
is the possibility of slight molecular mass changes to be detectable and quantifiable by a mass
spectrometer in large scale approaches and not by any other technology.
The use of stable isotopic labeling for relative protein quantification can be achieved by three
different methodologies: enzymatic, as the incorporation of 18O upon the protein digestion;
chemical, as the incorporation of mass tags in lysines and amine-terminus of proteins or
peptides; or metabolic labeling with the incorporation of heavy amino acids during protein
synthesis [10].
The quantitative analysis for each approach may be performed at different levels, where some
labels have mass differences that are detected (and quantified) in the precursor mass spectra
(MS1), and others are based on isobaric labels that lead to peptides with the same m/z but can
be distinguished (and quantified) at the fragment level (MS/MS) [9].
Each approach has its advantages and limitations, and are appropriate for different analysis
depending on the biological question and on the type of sample to be used [11].
2.1. 18O enzymatic labeling of peptides
The first trackable use of stable isotopes for quantification in neuronal tissue was used by
Desiderio and colleagues by isotopically labeling peptide internal standards for the absolute
quantification of neuropeptides [12]. To achieve this purpose, the authors used for the first
time enzymatically incorporated 18O (from H218O) in the carboxylic end of the peptides [12].
Although the strategy has been used since then, it was only in 2001 that it was first reported
in a study of untargeted relative quantification of the proteome of two types of adenovirus [13].
Since this first introduction, the enzymatic incorporation of 18O by serine proteases has been
widely used to compare the peptides produced from the protein digestion of distinct samples
(usually a control sample versus a sample from the condition under study). In general, the
incorporation of the heavy oxygen molecules is achieved by performing the protein digestion
in H218O using trypsin, although other enzymes such as chymotrypsin, lysine carboxylase
(LysC), or GluC may also be used [13]. With this approach two oxygen atoms are introduced
in the C-terminus of each generated peptide, resulting in a shift of 4Da in the mass spectra of
the peptide when compared with the peptides obtained from the sample digested with regular
water (Figure 2A) [14].
The advantages of 18O enzymatic labeling are: the fact that virtually all the produced peptides
are labeled and co-elute with the correspondent unlabeled peptide; the only reagent specifi‐
cally required is H218O; and the procedure is easy to adapt in any proteomics lab [15, 16]. On
the other hand, the procedure is labor-intensive and time-consuming; the labeling efficiency
is influenced by many factors (such as pH, enzyme to be used, or the characteristics of the
proteins and the peptides); and also if the 18O-water to be used is less than 95% pure, some of
the peptides will be labeled with only one 18O, resulting in a mass spectra with both 2 Da and
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Figure 2. Representation of spectra and labelling molecules from different quantitative labeling techniques. A) Repre‐
sentative spectrum used for peptide identification and quantification in a 18O quantitative approach with the represen‐
tation of the molecules with 16O and 18O. B) SILAC technique with representative spectrum used for peptide
identification and quantification accompanied by the representation of regular and heavy lysine. C) ICAT molecule,
where the X may be hydrogen or deuterium and an example spectrum used for peptide identification and quantifica‐
tion. D) Representation of the iTRAQ 8-plex molecule and the spectra obtained in an iTRAQ experiment with the
MS/MS spectrum that is used for identification and a zoom of the low m/z region where the reporter ions are used for
quantification.
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4 Da mass shifts [15]. Finally, the naturally abundant isotopes may also contribute to the peak
intensities making the spectra very complex to analyze and adding the necessity for improved
software for data processing [16].
In 2009, an updated 18O labeling method was introduced, the acid-catalyzed labeling of the
peptides, which, instead of the direct labeling of the peptides during the proteolytic digestion,
it was able to separate the digestion from the labeling step, being the last performed under
acidic conditions [17]. This protocol aimed to increase the distance between the unlabeled and
the labeled peptide in the mass spectra (as the acidic amino acids also incorporate the heavy
oxygen molecules) and also decrease the tendency of back exchange from 18O to 16O that was
reported [17, 18]. However, the incubation in acidic conditions is prolonged, may lead to acidic
hydrolysis of the peptides and deamidation of some amino acids that would increase the
complexity of the spectra [18].
In order to overcome the high time consumption of the procedure, many accelerating techni‐
ques have been applied, such as heating, high pressure, or ultrasonic energy [15]. Also, other
methodologies have been used, such as “inverse labeling”, which aims to decrease the
influence of naturally occurring isotopes [19]. Other 18O labeling approaches have been
proposed throughout the years, as the incorporation of the 18O molecules in cysteine (Cys)
residues at the protein level by the use of 18O-labeled iodoacetamide (cysteine alkylating agent)
[20] or the analysis of glycoproteins after specific enrichment [21].
This 18O labeling strategy has been employed to several types of samples, such as samples from
the CNS, for instance, for the differential expression study of proteins in the hippocampus of
rats subjected to traumatic brain injury [22] or for the quantitative profiling of CNS myelin-
associated proteins in the adult mouse brain [23].
2.2. Metabolic labeling approaches
Although labeled media have been widely used in biological studies, it was only in 1999 that
it was first used to evaluate protein expression by 2-DE [24] or phosphopeptides [25] in
microorganisms. Nonetheless, after the introduction of SILAC (Stable Isotope Labeling by
Amino Acids in Cell Culture) in 2002, metabolic labeling approach gained higher visibility [26].
Briefly, SILAC methodology consists of growing two populations of cells, one in the presence
of normal (light) medium and the other in the presence of medium that contains heavy essential
amino acids [27]. The labeling of the amino acids can be achieved by substituting hydrogen
for deuterium, 12C for 13C or 14N for 15N [27], and this leads to an expected mass shift in the
peptides coming from the heavy medium-grown cells that is visible in the mass spectra of the
peptide (Figure 2B) [28]. A shift from the first report using deuterated leucine [26] to the use
of labeled lysine and arginine with 13C or 15N has been employed, much due to the properties
of the enzyme to be used (usually trypsin or LysC). In this way, virtually all peptides in the
sample will be labeled [28], and also eliminates the problem of some deuterated peptides
eluting at different retention times than the unlabeled analogue [29]. In order not to introduce
quantitative errors in a SILAC experiment, all the proteins must be labeled; therefore, the cells
must be kept in culture with medium supplemented with dialyzed serum (to avoid unlabeled
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amino acids) for at least five passages in order to have at least 97% labeling [26, 28], although
a study of the labeling efficiency is advisable whenever a new cell line is used [28].
The major difference between this approach and others is that the labeling of the proteins is
performed metabolically, and also the mixing of the samples to be compared is performed in
the first steps of sample preparation leading to less variability in the results (Figure 3) [30].
Other advantages of the use of SILAC is its ease of use and implementation and also the
possibility of multiplexing (up to 5 samples per experiment) [9, 30].
While it was proposed initially that dialyzed serum should be used to avoid the presence of
non-labeled amino acids, this fact posed as a challenge for some cell culture types. In contrast,
many studies have already been performed with regular serum, proving that this extra caution
may not be necessary [30].
Over the years SILAC has been adapted to different cell types and with many different
applications, such as the analysis of protein-protein interactions [31], identification and
quantification of PTMs (for example by using methyl SILAC with labeled methionine [32]) and
protein modification dynamics [33], measurement of proteome translation or turnover (by
applying pulsed SILAC) [34, 35], or secretome protein quantification [36, 37].
Thus, SILAC has been applied to try to answer many neurobiological questions since it was
introduced; and in the last years, many studies have been published using this technique in
many different areas, such as the psychiatric field with studies of alcohol abuse [38] and
schizophrenia [39]; in neurodegenerative diseases by studying the functions of Parkin [40]; or
apoptosis in a neuroblastoma cell line [41].
The first rationale about SILAC was that it could only be applied to immortalized cell lines
and never to cultured primary cells. However, there are now many published studies that use
this technique in primary cells [9, 42], namely in primary neuronal cell lines, as in a study of
neuronal phosphotyrosine proteome in response to stimulation by a neurotrophic factor [43];
in a quantitative analysis of synaptic proteins from cultured cortical neurons from a mouse
model of mental retardation [44]; in the analysis of microtubule dynamics in rat hippocampal
neurons [45]; or even by enabling the analysis of primary cultured astrocytes proteome and
secretome [46]. Also, a strategy to diminish the number of passages necessary for the complete
labeling in cultured primary neurons (60% after 6 days and 90% after 10 days) was proposed
by multiplexing SILAC and using labeled amino acids for all the samples so that the protein
labeling incorporation rate may be the same in both samples (because both samples will have
the same heavy/light incorporation ratio) [47, 48].
In neuroprotemic studies, although neuronal-derived immortalized and primary cell lines may
be considered good simplified models, the use of mammal models (such as rodents) are
considered to be more complete. The general principle of SILAC was to add heavy amino acids
to cells in culture, making this approach incompatible with animal models. One of the first
attempts to overcome this challenge was by using the SILAC approach in cultured Neuro2A
cells and then mix them with mouse brain samples to work as internal standards [49]. The first
mammal to have the entire proteome labeled in vivo was a rat being fed with protein-free diet
supplemented with algal cells enriched with 15N [50, 51]. In 2008, the first mouse model to be
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labeled in vivo by using a heavy amino acid 13C-Lysine [52] was introduced. This new strategy
was named SILAM or Stable Isotope Labeling (by Amino Acids) in Mammals, and it has been
applied in several topics of the neuroscience field as the quantification of the synaptossomal
proteome of the rat cerebellum during development [53] or the proteome relative changes in
barrel cortex synapses upon sensory deprivation in mice [54].
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Figure 3. Comparison of the quantitative procedures of SILAC and iTRAQ.
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In what concerns neuroproteomics, the labeling of brain tissue in vivo is a great advantage,
although in order to be able to completely label all proteins in the brain of rodents it is necessary
to feed the animals with a special “heavy” diet at least for two generations, making this
approach time-consuming and expensive [52, 55, 56]. Therefore, one of the most promising
possibilities of SILAM is to use tissue from control SILAM-labeled animals as internal
standards to compare between unlabeled conditions [57, 58].
Also, because of this drawback, the super-SILAC approach was introduced, where multiple
cell lines are labeled with SILAC and are afterwards used as internal standards to compare
with unlabeled tissue [59, 60]. This technique was firstly introduced with cancer cell lines in
2010, but it has recently been applied to the study of mitochondria from mice brain by using
a super-SILAC mix of mouse brain mitochondria [61].
It was recently observed that the energy required to break down a nucleus into its component
nucleons (nuclear binding energy) is different for each isotope of every element leading to a
so-called “mass defect” (a mass difference of 6 mDa in the same molecule when a 12C is
exchanged by a 13C atom and a 15N for a 14N) led to the hypothesis that a calculated incorpo‐
ration of isotopes into proteomes would generate a MS1-centric quantification technology
combining SILAC with the multiplexing capacity of isobaric tagging (see below) [62]. This new
approach is named neutron encoding (NeuCode) SILAC, where peptide identifications are
generated using the MS1 scans collected at 30,000 resolving power, where the same peptide
with multiple labels will appear as a single peak in the spectra, whereas to obtain the quanti‐
tative information a higher resolution (480,000) MS1 scan is used, where the isotopologues can
be resolved and the quantitative information extracted as for normal SILAC (with a mass shift
of 36 mDa instead of 4 or 8 Da) [62]. This approach has the advantage of decreasing redundant
acquisition of fragment spectra for the same precursor ion (as in classical SILAC), and because
the quantitative information is acquired at the MS1 level, it is not dependent on peptides
selected for MS/MS and is not subjected to dynamic range compression caused by co-isolation
of precursor ions (as in isobaric labeling, see below) [62, 63].
In these first reports, the authors claim that the NeuCode approach may be used for 12-plexing
by using 3-plex SILAC, each one combined with 4 isotopologues, resulting in four distinct
peaks in a high-resolution spectra [62, 63], although it has already been used for 6- and 18-plex
in yeast cells proteome [64]. This approach has already been used in other applications, such
as C-terminal product ion annotation, based on the fact that all the y-ion in the fragment spectra
will appear as doublets [65, 66], or in top-down proteomics (analysis of the intact proteins
instead of peptides resulting from protein digestion) [67]. The major disadvantage of this
technique is that it requires MS equipments capable of high-resolution powers (≥480,000);
nonetheless, this approach is expected to be easily adapted for neuroproteomics research.
2.3. Chemical labeling approaches: Isotope techniques
The first technique using isotope labeling probes was called isotope-coded affinity tag (ICAT)
and was introduced in 1999 [68]. In this approach, a specific reagent (“tag”) is added to the
cysteines of proteins, once this tag has a thiol-specific reactive group, a linker with 8 deuteriums
in the heavy form, and a biotin affinity tag [68]. The procedure is simple and based on some
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basic steps: first the protein extracts must be isolated and the cysteines reduced, then the
proteins are labeled with the heavy or light ICAT molecule and joined for protein digestion;
the labeled peptides are enriched with an avidin affinity chromatography and analyzed by
LC-MS, where for each precursor a pair of ions will be visible with a mass shift in MS1 mass
spectra (Figure 2c) [68].
This first ICAT molecule was designed with 8 deuteriums leading most of the times to a
difference in retention times of the homologue peptides, where the labeled peptide does not
co-elute with its unlabeled pair, making the spectra analysis very difficult. Also, this mass
difference of 8 Da may be confused with other biological modifications (such as a peptide
containing 2 cysteines and an oxidation of methionine, both leading to a 16 Da mass shift).[69]
On the other hand, the ICAT tag itself was quite large contributing with a mass addition
sometimes bigger than advisable and leading to many fragments in the MS/MS spectra,
complicating the identification of the peptides’ sequence [69].
Due to these limitations of the initial approach, new strategies were introduced based on the
same principles, but with a cleavable site introduced to the tag [69, 70] or also the possibility
of labeling the sample in a solid-phase format [70]. This new cleavable ICAT (cICAT) has an
acid-cleavable linker group connecting the biotin with the thiol-reactive isotope tag and uses
9 13C instead of the 8 deuterium, this way, after labeling and chromatographic enrichment, the
biotin moiety is cleaved giving rise to a smaller modified peptide [69].
This ICAT strategy has already been applied for different approaches as the creation of
aldehyde-reactive tags (hydrazide-functionalized) isotope-coded affinity tag (HICAT) for the
identification and quantification of lipid-conjugated proteins [71].
This isotope-labeling technology has been applied in several neuroscience projects such as the
study of the influence of aging in the proteome of CSF (cerebrospinal fluid) [72], the study of
differential mitochondrial proteins analysis in the pathophysiology of Parkinson’s [73] or
Alzheimer’s diseases [74], and also to aid the study of the expression of synaptosomal protein
in cerebral ischemia [75], migraine mouse models [76], or in the study of addiction [77].
The greatest limitation of this approach is the fact that only peptides containing cysteines
are labeled and enriched, making these the only candidates for protein identification and
quantification,  leading most  of  the times to poor sequence coverages.  For this  reason,  a
similar strategy, ICPL (isotope-coded protein labeling) was developed, which, instead of
labeling sulfhydryl groups labels all free amine groups [78]. This strategy is very similar
to ICAT, with the exception that it has specificity for primary amine groups (lysine side
chains and N-termini), and has no biotin moiety so the option to enrich labeled peptides
does not exist. On the other hand, it is expected that at least 70% of all peptides will have
labeled  lysines  [78,  79],  or  virtually  all  the  peptides  if  the  labeling  is  performed  after
digestion (post-digest ICPL) [79, 80].
This post-digest ICPL can be combined with other fractionation methods such as IEF prior to
LC-MS [81] or even with enrichment of peptides with specific PTM’s as phosphorylation or
glycosylation [82].
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The original ICPL molecule could be multiplexed for three samples where the molecule had
0, 3, or 7 deuterium (d0, d3, and d7 molecules, respectively) [78], but is commercialized in a 4-
plex version allowing the labeling with 0, 4, 6, and 10 Da mass shifts and may be labeled with
deuterium or 13C [9]. Although this approach is not widely used it has the capacity to be applied
successfully to any protein samples, and it has already been used to study the proteome of
postmortem prefrontal cortex from control and schizophrenic patients [81, 83] and in biopsy
tissue samples from patients with glioblastoma [84].
As for SILAC, very recently, the NeuCode strategy described above has been applied to
chemical labeling with the development of an amine-reactive mass tag that takes advantage
of the differential neutron-binding energy between 13C and 15N isotopes that enables up to 12-
plex MS1-based protein quantification [63]. Another NeuCode approach proposed is to use
carbamylation of amine groups via urea isotopologues for protein/peptide labeling, and
therefore relative quantification [85].
2.4. Chemical labeling approaches: Isobaric techniques
All the methods described above use isotopic labeling of the proteins or respective peptides,
this way the calculation of the relative amounts is achieved by the analysis of the intensity of
the precursor ion peaks at the MS1 spectra. In 2003, a revolutionary variation of these techni‐
ques was introduced where the mass tag that was added to the peptides is isobaric, making
all the precursor ions from the samples in study appear as a single peak in MS1, but upon
fragmentation it leads to the formation of reporter ions separated by 1 Da coming specifically
from each of the samples [10]. The first approach applying this principle was called Tandem
Mass Tag (TMT) and in this first report synthesized peptides with the tag were used [86]. A
year later another approach was described, the isobaric tags for relative and absolute quanti‐
fication (iTRAQ). This concept was applied for the first time to label global proteomes (yeast
in this case) and even with the advantage of allowing the simultaneous analysis of 4 samples
(iTRAQ 4-plex) [87].
The molecule used to tag the proteins or the respective peptides after digestion for both
approaches, iTRAQ and TMT, has three main components and the principles are the same,
although structurely different between the two methods (Figure 2D). The molecules are
constituted by an amine-reactive group, which links the reagent to lysines and N-termini of
the proteins or peptides; by a reporter group, which has differential labeling with isotopes (13C,
15N or 18O) and is, upon fragmentation, the monitored ion for quantification in the MS/MS
spectra; and also a balancer group, which aims to keep the overall mass of the reagent equal
among all labels and is also differentially labeled with isotopes. [10]
A few years after this first introduction of TMT and iTRAQ, the neuroproteomics field had the
highest multiplexing usage of these approaches, in this case by studying proteomic changes
in CSF of patients with Alzheimer’s disease undergoing intravenous immunoglobulin
treatment with iTRAQ 8-plex [88] and by comparing CSF proteome in postmortem versus
antemortem drawing of the samples using a 6-plex TMT approach [89]. In 2012, upon the
substitution of a 13C for a 15N in two of the 6-plex tags it was noticed that the new tags were
6.32 mDa lighter, this way an 8-plex approach was developed even without changing the
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structure of the molecule but only by changing the isotopologue used [90], and it was hy‐
pothesized that a 10-plex or even 18-plex approach was possible [90]. In fact, TMT is commer‐
cially available in four different kits (TMTzero, TMTduplex, TMTsixplex, and TMTtenplex),
whereas iTRAQ is commercially available in two versions (iTRAQ 4-plex and iTRAQ 8-plex).
The TMT tags give origin to reporter ions in the 126–131 Da region of the MS/MS spectra and
the molecules used in all the available kits have the same structure. On the other hand, the
iTRAQ 4-plex and 8-plex molecules, which generate ions in the 114–117 Da and 113–121 Da
(except the 120 because of phenylalanine immonium ion contamination), respectively, have
different structures [10, 91].
Isobaric labeling of the proteins and quantification at the MS/MS level (outlined in Figure 3)
has the advantage of each precursor ion appearing as a unique peak leading to an increase in
sensitivity both at the MS and MS/MS level with no increase in mass spectra complexity [87,
92]. On the other hand, it is now known that the reporter ions of isobaric tags are prone to ratio
compression, meaning that together with the target precursor ion some contaminating near-
isobaric ions can be co-isolated and fragmented, contributing to reporter ion intensity and
biasing of the quantitative information [92, 93]. This fact leads to a ratio compression around
the unit, because when reporter ion intensity has interference from reporters coming from
peptides derived from proteins with unchanged expression, the ratio between the two samples
tend to be 1 [93]. To overcome this drawback, an MS3 strategy has been developed [93], as well
as its combination with synchronous precursor selection (SPS) [93], and although with these
strategies the accuracy and precision is enhanced it comes with the cost of a reduction in the
number of proteins quantified [11].
Some comparative studies have been performed between the different isobaric methodologies,
and when comparing 4-plex with 8-plex iTRAQ, the latter led to more consistent ratios without
compromising peptide identifications [91]. On the other hand, in another report, when
comparing TMT 6-plex with the two versions of iTRAQ, the 4-plex iTRAQ performed better
in terms of peptide identifications and similarly in terms of precision of peptide-spectrum
matches [94]. These discrepant results may be due to the use of different equipments and
softwares for data analysis. [10]
The amine reactive tags were the first ones to be developed and are also more commonly used.
However, new molecules have been developed to label other protein residues or PTMs. Both
methods have been adapted for these applications, TMT has been adapted for iodoacetyl cys-
reactive tandem mass tags (iodo-TMT) to identify and quantify S-nitrosylated peptides [95],
carbonyl-reactive TMT (glyco-TMT), which may be used with two different chemistries, either
aminoxy-TMT or hydrazide-TMT, and enable quantification both at the MS1 (coded with
isotopes) and the MS/MS (coded with isotopic reporters) [96]. iTRAQ has also been adapted
for the detection and quantification of carbonylation of proteins by means of functionalizing
the iTRAQ molecule with hydrazine (iTRAQH) [97], for phosphoproteome identification and
quantification (phospho-iTRAQ) [98], and also for identifying new N-termini generated by
proteases in a strategy combining iTRAQ with terminal amine isotopic labeling of substracts
(TAILS) [99, 100].
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TMT and iTRAQ technologies have been extensively used by the scientific community to
answer several biological questions and applied to almost all types of samples. In neuropro‐
teomics, these approaches have been extensively used to characterize the differential pro‐
teomes of neuronal disorders, drug responses or brain regions. Many studies have been
performed using these techniques in areas such as neurodegenerative disorders, as the study
of the putamen proteome of an MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) monkey
model of Parkinson’s disease [101] or in the serum of Parkinson’s disease patients [102], or
even in the analysis of synaptossomes from cortical brain tissues from Alzheimer’s disease
patients [103]; in neuropharmacoproteomics, as in the examples of a study of protein quanti‐
tative alterations induced by antidepressants in the hippocampus of mice [104]; also in
addiction as in the evaluation of the effects of administration of plasminogen activator after
ischemic injury in mice [105] or the alterations upon chronic exposure to cocaine [106]; in
neuropsychiatric and other CNS disorders, such as schizophrenia, with the study of protein
expression in the thalamus and CSF of patients [107] and a study of neurofibromin knockdown
PC12 cell line as a model of neurofibrimatosis [108]; or even in studies of neuronal function
such as memory formation in hippocampus [109].
Once, these commercially available isobaric tags were expensive and laborious to produce, in
2010 two new isobaric approaches were proposed, N,N-Dimethyl Leucines (DiLeu) [110] and
deuterium isobaric aminereactive tag (DiART) [111], which should serve as cost-effective
alternatives to iTRAQ and TMT [10].
DiLeu was developed inspired by the chemical isotopic labeling by formaldehyde dimethy‐
lation of lysines [112], which is an inexpensive approach, and the aim is to combine it with
isobaric labeling and quantitation at the MS/MS level [110]. This way a 4-plex set of dimethy‐
lated leucines for amine groups labeling was developed, and has a structure similar with the
other isobaric approaches, with an amine-reactive group, a balance group, and a reporter
group (115–118 Da) [110]. DiLeu has a labeling efficiency similar to iTRAQ and generates
reporter ions with higher intensity; nonetheless, this approach requires an extra step of
activation of the reagents prior to the labeling reaction because it uses a different chemistry [10,
110], and is also prone to the co-isolation of precursor ions (as iTRAQ and TMT). Recently,
DiLeu was used to test if the implementation of ion mobility MS would mitigate this phe‐
nomena [113].
The DiLeu strategy has already been applied to study the neuropeptidome of a crustacean
species [114], and for relative quantification of amine-cointaining metabolites [115]. A 12-plex
DiLeu strategy has been introduced that takes advantage of changing isotopologues in the
reporter groups, similarly to NeuCode or TMT 10-plex [116].
DiART was designed as a less expensive 6-plex isobaric labeling reagent to label amine groups
of proteins and peptides and is, once more, based in a very similar structure as iTRAQ and
TMT using an amine-reactive group, a balancer group, and a reporter group in the mass range
of 114–119 Da. [111, 117] In a study comparing DiART and iTRAQ, the authors found that
DiART leads to more intense reporter ions and consequently less ratio compression, however
with the DiART approach, the common fragmentation method is not advisable due to easy
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reporter ion fragmentation [118]. DiART has also proven to be compatible and valuable for
PTM analysis as quantitative phosphoproteomic studies [119].
Although isotopic and isobaric techniques are based in different methods of quantification and
have strengths and drawbacks, both have proven to be valuable for quantitative proteomics
[11] and the combination of several methods has been applied to increase throughput of the
analysis. This combination is called hyperplexing, because it enables the simultaneous analysis
of a higher number of samples, such as with the combination of metabolic 3-plex labeling with
isobaric 6-plex TMT that enables the analysis of 18 samples [120], also it is expected that by
combining different strategies an even higher throughput and more reproducible results will
be achieved [10]
3. Label-free approaches
As an alternative to the labeled methods, several label-free approaches (Figure 4) have
emerged, some of them with comparable accuracy to the labeled methods and all of them with
similar or higher proteome coverage and dynamic range [121, 122]. These methods gained
popularity mainly due to their low cost, their simple sample preparation, the unlimited
number of samples that can be compared, and their multiple applications [121]. These
attributes turn label-free methods into a powerful technique for clinical applications and large
screenings. However, as samples are analyzed separately, these types of methods are highly
dependent on run-to-run reproducibility, therefore sample preparation and analyzes should
be well implemented and standardized. Furthermore, the methods rely also on the software
capacity for both data extraction and capacity to accommodate errors [123, 124].
In general, label-free approaches can be divided into two distinct groups according to the
method used for data extraction. On one hand, the quantification can be inferred by counting
the number of peptides or spectra assigned to a given protein, and therefore are generically
called spectral counting methods. On the other hand, when liquid chromatography is coupled
with mass spectrometry, quantitative values can be measured through the extraction of the
area of the precursor ions’ chromatographic peaks - area under the curve (AUC) or MS1 signal
intensity methods. [121-123]
Traditionally, label-free methods were associated with the commonly used shotgun ap‐
proaches, where mass spectrometry instruments operate in a data-dependent acquisition
mode (DDA, also called information-dependent acquisition or IDA) (Figure 4A). Therefore,
these methods have also the advantage of being used in data previously acquired for protein
identification [125, 126].
In this type of experiments, the instruments are set to scan the precursor ions followed by the
selection of a limited set to be fragmented, usually the most intense ones. The fragmentation
spectra (MS/MS spectra) obtained will then be used for peptide identification. Independently
of the method used to extract quantitative information, the mass spectrometers working on
IDA mode must be fine-tuned in order to acquire enough data to perform both the identifica‐
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tion and the quantitative analysis [127]. This is particularly important for MS1 quantification
methods, where enough points per chromatographic peak to perform an accurate extraction
should be acquired, without misplacing the acquisition of good fragmentation spectra that
allows peptide's identification. Although this balance is not so crucial for the spectral count
methods, it is also important to have a good balance between survey and fragmentation scan
in order to be able to achieve a higher proteome coverage. Therefore, the development of mass
spectrometers with faster scans combined with higher resolution power has been fundamental
for the increase in the use of label-free approaches [122, 125].
Label-free methods still rely on peptide identification, the IDA experiments tend to be biased
to the most abundant proteins and are highly affected by sample complexity/dynamic range.
Therefore, the use of data-independent acquisition (DIA) methods, where fragmentation
spectra is acquired for the entire sample without any pre-selection of precursor ions, soon
started to be used for label-free quantitative approaches as an alternative to the limitations of
IDA experiments [122, 126].
Finally, although label-free approaches are mainly a method for relative quantification (Figure
4B), several groups have also taken efforts to evaluate the relationships between label-free
measurements and absolute quantification (Figure 4C) of proteins in complex samples. And
in fact, several adaptations came out as good correlations between label-free measurements
with protein concentration, allowing the use of label-free methods for the determination of the
absolute abundance of a protein [122, 128].
3.1. Spectral counting-based label-free methods
Spectral counting methods consist of simply counting of the number of peptides and/or
fragmentation spectra of a particular protein, and comparing the value between conditions.
Within this group of label-free methods, it is possible to distinguish some different types: 1)
those that are based on unique peptide counting; 2) those based on MS/MS counting (SpC);
and finally, 3) an adaptation of spectral counting, spectral TIC counting (MS2 TIC) [132].
3.1.1. Peptide counting and Spectral Counting (SpC)
The correlation between the number of peptides acquired in an IDA experiment with the
protein abundance was firstly reported in 2001 by Washburn and colleagues [133]. In this work,
the authors used the codon adaptation index (CAI) as a measurement of the protein abun‐
dances, and correlated CAI ranges with the number of proteins identified and the number of
peptides identified per protein. CAI relies on the evidence that mRNAs of highly expressed
proteins preferably use some codons (those of which the tRNAs are present in the greatest
amounts) rather than others specifying the same amino acid [134], and at that time it was
already proved to correlate well with protein levels [135]. With this assessment, Washburn
and colleagues were able to note that the most abundant proteins were identified with multiple
peptides, while for the low abundant proteins the identification was achieved based on one or
two peptides. Although no special focus at the quantitative level was performed, this evidence
would be the basal principle of the spectral counting approaches [133].
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Figure 4. Overview of the label-free MS-based quantitative methods, instrumental principles and data analysis. (A)
Comparison of the MS instrumental principles of the acquisition modes most commonly used in label-free approaches:
1) Information Dependent Acquisition (IDA) where fragmentation spectra are only acquired for a group of selected
precursor ions based on their intensities; versus 2) Data Independent Acquisition (DIA) where fragmentation spectra is
acquired for all the precursor ions independent of its intensity. Fragmentation spectra can be acquired for the entire
mass range simultaneously (MSE) or by covering the mass range in sequential smaller windows of defined size
(SWATH-MS). (B) Schematic representation of the different label-free approaches for relative quantification. In the
spectral-counting (SpC) approach, peptide/protein abundances can be estimated based on the number of identified
MS/MS spectrum. In the MS2 TIC approach, peptide/protein abundances can be estimated based on the mean of the
TIC (sum of all the fragments in a given MS/MS spectra) off all the identified MS/MS spectrum. In the precursor ion-
intensity-based approach (for both IDA and MSE method), the changes of peptide/protein abundances are determined
by measuring and comparing the chromatographic peak areas of the corresponding peptides. The changing peptides
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are subsequently identified based on the respective MS/MS spectra (IDA) or a recomputed pseudo-MS/MS spectra
(DIA). In the SWATH-MS approach, changes in confident peptides/proteins are determined based on the fragment ion
intensities (MS2 intensity), designed as peak groups of each preciously identified peptide. In this example, results
would indicate a higher peptide abundance in State A. (C) Representative examples of label-free methods for absolute
quantitative proteomics. In the case of the strategies based on MS1 intensities, the average of the three most intense
ions (TOP3) and the iBAQ index are used to generate reliable absolute quantitative data. In the strategy based on spec‐
tral count, both emPAI and APEX strategies used the number of identified peptides normalized for the expected num‐
ber of peptides (to reduce the impact of protein size) as an indicator of the protein abundance. As an example, proteins
A and C, present at the same abundance, have different spectral counts but they present the same normalized spectral
count. Adapted from [129–131].
At the end of the same year, the first quantitative report based on the spectral counting
principle was published by Pang et al. [136]. In this work, the authors introduced the concept
of peptide “hit” (now known as peptide hits technology or PHT [137]) as a measure to estimate
the relative changes in protein abundance. In this method, each hit corresponds to one
identified peptide and the protein abundance is calculated by summing all the hits. The method
assumes the principle that the coverage of the protein increases in proportion to the protein
abundance, which is reflected in the number of peptide hits of a given protein. In the same
report, the authors applied this quantitative method to the identification of biomarkers for
inflammation in urine samples of healthy vs. disease conditions, and performed a comparison
between the proposed approach and the usual quantitative 2D-gel approach. Similar quanti‐
tative results were obtained between the methods studied, with a significant increase in the
number of the proteins analyzed in the gel-free approaches combined with a significant
reduction in the required amount of sample and sample processing [136].
In 2003, Gao et al. [138] applied for the first time a statistical method (Student’s t-test), already
widely used for gene array experiments, in peptide hits quantitative data in order to quickly
assess with statistical significance the abundance changes° between treatments/conditions.
The use of such method into quantitative proteomics was evaluated in a widely used biological
system by performing a comparison with the results obtained in previous reports, revealing a
high degree of concordance. Therefore, the use of such statistical evaluation can quickly
highlight the proteins that are in fact altered from the entire data set of proteins analyzed in
larger screenings, turning the data analysis into a more automated and reliable method [138].
After the initial report using peptide hits as a quantitative measurement of protein levels [136]
and following the same principle stated in that work, some adaptations to that quantitative
method started to appear in order to take into account the protein characteristics that could
influence the results. Matthias Mann’s group was a pioneer in the development of such
adaptations, with the first adaptation appearing in 2002 by Rappsilber and collaborators [139].
In this work, the authors characterized the human spliceosome by an exhaustive identification
of the constituents of that multiprotein complex, and by obtaining the relative abundance of
the different classes of proteins involved. In order to do so, the authors presented a new method
to quantify protein levels, the protein abundance index (PAI), which consists of the number
of MS/MS spectra identified divided by the number of theoretically observable peptides, i.e.,
the theoretical peptides that will feat in the mass range of MS [139]. By considering the
theoretical number of peptides that can be formed from a given protein, the authors compen‐
sated the impact of the protein size, since larger proteins can give rise to more peptides within
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the MS mass range. However, once the authors considered all MS/MS spectra that originated
positive identifications from peptides acquired with different charge states to modified
peptides, the measured values also reflect the response of a given protein to the measurement
procedure and not only its abundance.
Soon, label-free approaches being performed in comparative screenings and some alternative
methods based on the principle stated above started to emerge. At the same time, two
independent studies focused on the proteome changes observed in the development stages of
the human malaria parasite Plasmodium falciparum were published presenting two alternative
methods to evaluate these proteomics changes. While Florens and collaborators [140] com‐
pared the protein sequence coverage between the development stages to estimate protein
relative abundance, Lasonder and colleagues [141] used the total number of unique peptides
identified and introduced the use of the extracted ion chromatograms (XIC) of individual
peptides as a method to confirm the absence or presence of a particular protein. With the use
of the MS-XIC evaluation, the authors overcame one of the limitations of IDA experiments
where it is possible that a peptide is not selected for fragmentation in a particular sample due
to changes in sample complexity [141].
Another disadvantage of spectral counting is that the length of the protein influences the
number of theoretical peptides that can be produced from tryptic digestions [142, 143].
Therefore, in order to overcome this limitation, several modifications were proposed to take
into account the protein size [121]. The most widely used is the normalized spectral abundance
factor (NSAF), proposed by Zybailov in 2006 [144], which consists of the normalization of the
SpC of a given protein by the protein length (L). These values are further normalized by the
sum of the SpC/L for all the proteins analyzed, thus taking into account the experimental
variation. Furthermore, this method presents a high dynamic range (~4 orders of magnitude)
and is able to measure smaller variations (lower than 50% variation) [144]. This method was
revised by the same group, presenting an improved NSAF approach that is able to deal with
peptides shared between proteins and the distributed normalized spectral abundance factor
(dNSAF) [145].
The use of shared peptides for quantification has been a critical issue since the abundance of
a peptide that is shared across proteins depends on the contributions of the multiple proteins
to which it belongs [127, 146]. Therefore, it is incorrect to overestimate the protein abundance
by counting the shared peptides multiple times, typically these peptides are simply ignored
in protein-level quantification analysis [147]. However, this may significantly decrease the
number of proteins for which it is possible to estimate its abundance (as much as 50%) [146].
Thus other approaches have been used to include these peptides. Some approaches try to
assign the shared peptides for a particular protein (the most abundant of the group) by taking
into account parameters such as the number of unique peptides to calculate the relative
abundance of each protein [148, 149]. dNSAF is perhaps the most known example of such type
of adaptation [145]. Finally, some authors also proposed to analyze the proteins that have
shared peptides as a protein group and not individually. However, these proteins can present
different regulatory mechanisms, therefore their combination fails to estimate the real
variation [150].
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3.1.2. Spectral TIC (MS2 TIC)
In 2008, Asara and colleagues [142] presented a new method for relative protein quantification
that could be considered an extension of the spectral counting technique. In this approach, the
average of the TIC for all of the MS/MS spectra that identified a protein was used as a quan‐
titative measure. Each spectral count gets a unique abundance value, which consist of the sum
of all the fragments in a given MS/MS spectra, instead of being just counted as one event. In
this study, the authors proved that this “spectral TIC” method was effective and expanded the
dynamic range of quantitative ratios allowing for larger protein abundance [142]. This would
allow to overcome one of the limitations of the spectral counting, its intrinsic tendency to easily
reach the saturation for the most abundant peptides, not being able to quantify properly large
protein ratio differences, and limiting the dynamic range of the method [122]. In this approach,
the authors counted all the MS/MS spectra that resulted in positive identification and the
average was used, instead of the sum of the TIC, in order to overcome the sampling bias caused
by different protein molecular weights (larger proteins generate more tryptic peptides than
smaller proteins). The proposed method was tested by evaluating its capacity to reach the
theoretical ratio of a known digestion mixture, and comparing it with other quantitative
methods already well established. With this comparison, the authors showed that the spectral
TIC has a similar accuracy to the AUC methods and is able to correctly calculate large variations
[142] and detect relative changes in low abundance proteins [151].
This method had some improvements; it was combined with data from the SpC method in
order to obtain a better characterization of the samples [152], also Griffin and collaborators
proposed a new normalized label-free method that combines the three MS abundance features,
namely the peptide and spectral counting with the TIC intensity [153]. This method, termed
normalized spectral index (SIN) combines the reproducibility already presented by spectral
counting methods with an increase in the accuracy of the determination of protein abundance
observed in TIC intensity methods. Furthermore, by correcting it for protein length, it also
reduced the samples bias to large proteins [153].
3.2. MS1 signaling intensity or Area Under the Curve (AUC)
Bondarenko and Chelius [154, 155], in 2002, were the pioneers of the use of MS1 signal intensity
as a measurement of protein levels. Bondarenko, in his technical work, tested the hypothesis
that peak area of the peptides should reflect its concentration and therefore those peak areas
should correlate with protein concentration. To test that, different amounts of a pure protein
were analyzed, alone or spiked in a complex mixture, and the extracted peptides’ areas were
compared with peptides’ concentration, revealing a high degree of correlation even in samples
with high complexity. Furthermore, the authors also proposed the use of a correction factor
designed as experiment-dependent correction factor that aimed to reduce the impact of some
experimental parameters, such as differences in sample preparation, that could lead to some
bias of the results. The use of such correction factor, which is determined from the mean
tendency of the non-variable proteins, proves to improve the accuracy of the quantification
[155]. Therefore, the use of normalization methods became a key feature in label-free quanti‐
fication, and several alternatives have been proposed. Those alternatives can be divided into
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two groups based on their basic principles. On one hand, some normalization methods are
based on the principle that a large portion of the proteome does not change, therefore the mean
tendency between experiments can be used to accommodate some experimental deviations.
On the other hand, the normalization for housekeeping proteins, a protein or set of proteins
known to be constant, or for an internal standard added to the samples before sample
processing can be used since both will reflect the effect of sample processing [155, 156].
The MS1 intensity label-free methods are highly accurate since they require the use of high-
resolution mass spectrometer in order to be able to distinguish the co-eluting species [121,
152]. Protein quantification based on AUC requires the comparative measurement of precursor
ions intensity at a particular retention time, therefore this type of quantitative methods is also
dependent on the power of data extraction algorithms, and several different methods are
already available [121, 125, 130]. Independently of the software used, the data analysis of MS1
intensity peaks generically comprises a set of defined steps: feature detection, alignment of
retention times, peak picking, noise reduction, and normalization of MS intensities [121, 130].
The detected and normalized peaks are then compared between the samples and their MS/MS
spectra are used for protein identification [121]. The estimation of the protein abundance can
be obtained mainly by three different strategies: by summing all the peptides considered in
the analysis; by performing the mean of all the peptides; or considering only the 3 most intense
peptides (usually using the mean value), the so-called TOP3 method [157, 158].
Since quantification is done at the MS1 level, the estimation of protein abundance is not
dependent  on  the  acquisition  of  a  particular  MS/MS  spectra  in  all  the  experimental
conditions. In fact, a given peptide can be identified in a single sample and quantified across
all  the remaining samples [141].  Thus, these methods are not so prone to the variability
associated with variation of  sample to sample complexity.  This  characteristic,  associated
with the unlimited number of samples to be compared, enables MS1 intensity methods as
suitable methods for clinical  biomarker discovery,  which normally requires high sample
throughput [125].
Due to the large number of modified methods and the generalized use of the terms spectral
counting and peak intensity to include all the modifications, it is not always clear which
particular method was used in a given experiment. Therefore, to simplify the categorization,
the reports are commonly grouped in these two generic categories, taking into account only
their basic principles.
The use of spectral counting and/or MS1 intensity methods in neuroproteomics is vast and
usually alternates between the use of one type or another [9, 159, 160]. However, some reports
combine the two methods to improve the results obtained, such as in the case of the interac‐
tomics study of the AMPA receptor performed in collaboration with our group [161] where
both spectral counting and MS1 intensity were used to identify the truly positive interactors
from the negative control. Within the areas where label-free methods are being used, it is
possible to identify some general studies focused on understanding proteomics changes in
brain regions, such as the evaluation of frontal cortex changes caused by frontotemporal lobar
degeneration (FTLD) [162]; cell- and tumor-specific alterations, such as the comparison of
astrocytes and astrocytoma proving evidences for the existence of important membrane
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biomarkers capable to define the cell lineage of the tumor [163]; and characterization of protein
architecture of secretory vesicles, key components that mediate intercellular signaling [164].
Although, regarding label-free approaches, the neuropsychiatric field is dominated by the use
of MSE, in the study of neurodegenerative diseases (such as Parkinson’s, Alzheimer’s, and
Huntington’s diseases) there is an evident tendency of spectral counting/peak intensity
methods [9] in both the analysis of cell and animal models (both obtained by the use of chemical
and genetic alterations) [165–167] and also CSF [168] and postmortem tissues (mainly in the
case of Alzheimer’s disease) [169, 170]. Those proteomics screenings led to the identification
of several deregulated proteins, contributing to an increase in the understanding of the
pathways that are altered in those disorders.
There is an inherent tendency for a larger number of spectral counting reports [162–165, 167,
169, 170] when compared with the peak intensity reports [166, 168], as observed from the
examples stated above. This underestimation of peak intensity reports from IDA experiments
is associated with the preference from the alternative peak intensity methods based on DIA
acquisition (such as MSE). Although in reduced numbers, there are also some reports on the
use of MS2 TIC methods, more specifically SIN, in the neuroproteomics field. As an example
of its applicability, there are two studies involving brain tumors. In one study, the authors
performed a characterization of the differentiation states of glioblastome stem cells (cells
responsible for tumor formation and growth [171]), in the other study the authors were focused
in the analysis of the secretome of glioma cells in order to identify the proteins that could be
involved in tumor cells migration [172].
Further quantitative neuroproteomics studies were already summarized in several reviews [9,
159, 160].
3.3. Data-independent acquisition methods
As stated above, in order to overcome the limitation of the use of IDA modes, alternatives with
DIA are starting to be used. The major advantage of this acquisition mode relies on its ability
to record fragmentation spectra from the entire set of precursors of a given sample, without
any selection that can bias the acquired data. However, in these experiments, the data analysis
is very challenging, since the link between the precursor and its fragments is lost [173], these
methods are highly dependent on the development of algorithms capable of extracting
valuable information from the data acquired [174].
These methods operate in a cyclic mode, throughout the entire liquid chromatography (LC)
time range, by alternating between survey and fragment ion spectra. Generically, these
methods can be divided into two distinct groups, those that acquire the fragmentation spectra
of the entire mass range simultaneously, and those that scan the m/z range in sequential
isolation windows of different widths. The use of sequential isolation windows is a way to
reduce some of this complexity, by decreasing the number of concurrent ions being fragmented
at a given moment [173, 174].
Usually in DIA experiments, the quantitative information is still obtained from the precursor
ion signal, while the fragmentation spectra are mainly used for peptide identification by both
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the use of common tools developed for DDA, or by searching pseudo MS/MS spectra recon‐
stituted based on co-elution profiles of precursors and their potential fragments [174].
Several DIA acquisition methods were developed based on the use of different mass spec‐
trometers and/or different dissociation methods (see Table 1) [173, 174], however, within this
chapter only the most used method, LC-MSE, and the SWATH-MS method will be presented.
Method Instrument m/z selection window(width) Dissociation method Ref
Shotgun CID Q-Tof Full m/z range CID in-source [175]
Original DIA Ion Trap 10 m/z CID in-collision cell [176]
MSE QqTOF Full m/z range CID in-collision cell [177]
p2CID Q-Tof Full m/z range CID in-source &collision cell [178]
PAcIFIC
(Percursor Acquisition Independent
From Ion Count)
Ion Trap 2.5 m/z CID in-collision cell [179]
All Ions Fragmentation (AIF) Orbi-Trap Full m/z range CID in HDC collisioncell [180]
XDIA or DIA-ETD-CAD IonTrap-ETD-CAD 20 m/z ETD in cell [181]
SWATH QqTOF 25 m/z CID in-collision cell [173]
Fourier transform-all reaction
monitoring (FT-ARM)
LTQ-FT or LTQ-
Orbitrap 12 m/z or 100 m/z CID in-collision cell [182]
Table 1. List of DIA methods (adapted from [173, 174]).
3.3.1. Liquid Chromatography-Mass Spectrometry Elevated energy (LC-MSE)
LC-MSE was the first label-free method from DIA used in proteomics quantitative screening.
This method is based in the neutral loss acquisition mode and was first reported in large
datasets by Wrona and collaborators in 2005 [183] as a “all-in-one” analysis for metabolite
identification. This method was further transposed to proteomics studies, mainly supported
by QqTOF instruments [177, 184]. MSE consist of the acquisition of samples in two alternate
modes, first samples are acquired in a low energy mode to collect precursor ions masses (MS
precursor scan) and then in a high-energy mode to induce the fragmentation of the entire
samples and acquisition of all the product ions (MS/MS scan) [184]. Over the years the coupling
with the continuous development of MS and LC systems (more specifically, the use of UPLC-
MSE), more reproducible and accurate quantification has been achieved. However, as an
inherent issue of DIA experiments, a large amount of data acquired remains unused, therefore
a considerable effort has been done in order to obtain algorithms capable to extract more
information from the acquired data than that already available [174].
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3.3.2. Sequential Window Acquisition of all Theoretical Fragment-Ion spectra (SWATH-MS)
In 2012, Gillet and collaborators [173] presented the SWATH-MS method, although at that
time other DIA methods were already widely used. It was a method that was particular‐
ly  innovator  due  to  its  proposed  data  extraction  methodology.  Here,  the  authors  pro‐
posed  a  targeted  data  extraction  by  combining  parallel  analysis  of  samples  with  an
optimized IDA method for peptide identification followed by a DIA acquisition to be used
to extract quantitative information. From the IDA method, a list (called “library”) contain‐
ing all  the information regarding a given identified peptide (such as RT, precursor m/z,
and MS/MS spectra) was obtained and it was further used to extract the XICs of the specific
fragment ions (called peak groups) from all the high confidence peptides identified. Thus,
instead of using the precursor intensity as performed by the other methods, in SWATH-
MS the use of MS2 signaling intensity-based method was introduced, which is similar to
the quantification already performed in MRM and PRM experiments,  for the untargeted
analysis of large fractions of the proteome. Furthermore, the authors also showed that with
SWATH-MS,  it  was  possible  to  achieve  similar  reproducibility  and  accuracy  as  for  the
targeted methods for protein quantification [173].
For the acquisition of the fragmentation spectra of virtually all the precursor ions present in a
sample, the mass spectrometer, a high-resolution Triple-TOF instrument, operates in the
sequential isolation window acquisition principle introduced by previous DIA studies [174,
176]. By fractionating the sample in SWATH acquisition windows, this method leads to a
reduction of the concurrently fragmented precursors and consequent reduction of the acquired
MS2 spectra complexity.
As data extraction is  performed by targeting the peptides already identified,  the loss of
precursor-fragments linkage is overcome, and a large percentage of data is effectively used.
Furthermore, this targeted data extraction also allows that additional criteria, such as the
transition intensity ratio, m/z error, and similarity to the identified MS/MS spectra, can be
used in combination with the usual chromatographic criteria to evaluate the confidence of
the peak group formed. Therefore, protein quantification is obtained from a more reliable
extracted data [185].
The SWATH-MS method seems to be able to overcome the majority of the limitations of
label-free methods, it is unbiased, presents a broad range of precursor ion fragmentation
(covering almost the entire mass range usually analyzed),  and it  relies on targeted data
extraction  [173],  thus  making  this  method  a  promising  strategy  to  be  applied  in  large
screenings, such as the discovery of biomarkers [9, 129, 186–188]. Although, being a very
recent methodology, the great expectation regarding its application into the biomedical field
is  reflected  in  the  several  improvements  already  achieved  into  the  different  domains
associated with this method. There are already improvements in the DIA acquisition mode
with the introduction of the variable windows mode where windows with different widths
are adjusted to the number of precursor ions per m/z range, thus the number of concur‐
rent ions are reduced in the most populated regions. Moreover, several different groups,
have  been  working  on  the  improvement  of  sample  preparation  and  library  creation  to
increase the number of proteins quantified per sample, as well as to obtain more reprodu‐
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cible data [189–193]. Finally, different algorithms were also developed to address SWATH
data, both in the targeted mode [194] and untargeted mode, which is mainly focused on
performing protein identification directly from the SWATH data [195].
The introduction of the concept of a protein library that can be used to interrogate multiple
samples has opened the door to the idea of having cell-, tissue-, and species-specific libraries
containing exhaustive lists of identified proteins capable of covering the entire proteome.
Those libraries can then be used in both research and clinical fields to extract larger quantitative
information from the analyzed samples. Within this scope, Aebersold and co-works have
already published the first repository with 10,000 human proteins that claims to successfully
detect and quantify 50.9% of all human proteins [196]. Furthermore, as the SWATH file of a
given sample corresponds to the MS/MS spectra signature of that sample, that file can be
interrogated any time it is required without the need to re-analyze the sample. Therefore, with
these SWATH files it is possible to create a repository of samples that can be used in longitu‐
dinal studies [129].
As stated above, the use of DIA in proteomics is recent and is not a common option, therefore,
this overview in the neuroproteomics field will be done for MSE, which is the most used
method, and also for SWATH-MS due to the exponential increase in the interest and devel‐
opment associated with this approach.
MSE is perhaps the most used large-screen, label-free method, particularly in the neuropro‐
teomics field, and the only DIA method that has gained enough visibility so far [9, 197].
Although MSE was also used in different neuroproteomics areas, such as in the studies of
frontotemporal lobar degeneration [198] and the profiling of phosphorylation events in
different rat tissues, including the brain [199], its use was particularly potentiated by the Sabine
Bahn group for the study of neuropsychiatric diseases, such as schizophrenia, major depres‐
sion, and bipolar disease [160]. In general, their published works were mainly focused on
differential analysis of human samples, both serum [200, 201] and postmortem tissue [202-204],
from patients versus healthy controls, or including different disease groups or groups with
different levels of antipsychotic medication. Those works aimed to identify differentially
altered proteins that could distinguish between the disease groups, but could also contribute
to a better understanding of the diseases. In fact, the authors were able to identify several
different proteins that are altered between schizophrenia patients versus controls, including
proteins altered in first-onset paranoid patients [201], and observed also some proteomics
alterations that were dependent on the dose of antipsychotic medication [204]. Finally, to
distinguish the effect of the medication from the disease alterations, Sabine Bahn’s group also
studied the modifications caused by some of the antipsychotic drugs in rat frontal cortex, being
able to identify proteins altered by the medication, some of them altered in both types of
medication used [205]. More recently, MSE was also used to perform proteomic profiles of the
first episode of major depressive disorder patients and sex-specific alterations of adults
diagnosed with Asperger syndrome [206].
Being a very recent method, SWATH-MS reports are mainly associated with technical
improvements, and in demonstrating its capacity to obtain large proteomics profiles with its
potential use to clinical studies and biomarkers discovery, such as the study of plasma PTMs
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as phosphoproteins [187] and glycoproteins [207], large screening of twins [208], and human
library creation [196], and also its applicability in biopsies specimens [188]. In the neuropro‐
tomics area, it is already possible to find some reports, such as the work published by our
group [209], where we presented a pipeline for reproducible quantitative screenings using a
membrane-enriched sample from rat cortex, indicating that our approach is suitable for
evaluation of membrane proteins, key players in the majority of neuronal dysfunctions. There
are also two other works from Fox’s group regarding mitochondrial alterations: one of them
corresponding to an exhaustive characterization of mitochondrial proteome from embryonic
and postnatal rat brain revealing a rearrangement of proteins from glycolysis and mitochon‐
drial trafficking/dynamics, which may suggest a development change to accommodate the
required energy demands in different developmental stages [210]. Another study focused on
mitochondrial functional alterations associated with deregulation of PTEN-induced kinase 1
(PINK1), a Parkinson’s disease-associated protein [211].
3.4. Absolute quantification based on label-free approaches
Although the majority of the screenings are based on relative quantification, some authors
started to focus on the possibility to also extend these methods to absolute quantifications
[128], since the calculation of the protein abundances in a sample is essential to increase the
understanding towards the biological systems and its variations [177, 212]. Overcoming the
elevated cost and demanding sample preparation of an isotopic dilution-based method to
perform absolute quantification, the use of label-free techniques reveals a reliable alternative
(although less accurate than the referred methods). The available methods can be divided into
two generic classes based on the quantification algorithms used: 1) those based on tandem MS
data, e.g., protein sequence coverage or spectral counting including emPAI [213] and APEX
[214]; and 2) those based on the measurement of precursor ion intensity such as MSE [177],
T3PQ [157], and iBAQ [215].
In general, all these techniques were described as having good correlation with protein
amounts in both simple mixtures of proteins with known amounts (alone or spiked in complex
samples) and for unknown proteins in complex samples. When complex samples were used,
the accuracy of the results were confirmed by comparing the values achieved within several
different techniques, such as other mass spectrometry-based quantitative methods (including
isotopic labeled methods), transcriptomics analysis, and ELISA [157, 177, 212–215]. In all cases,
a proper estimation of the protein abundance was achieved with or without standards.
The more cost-efficient and easier option is to exclude the standard proteins and calculate
protein abundances from the fraction of each protein in the total protein pool assuming that
most of the proteins that contribute to the total protein pool are identified and quantified. As
examples of this quantification without standards, it is possible to find the determination of
the copy number (using total protein approach (TPA) [216]) and the definition of the stoichi‐
ometry of protein complexes [217]. However, the quantification accuracy can be increased by
using a standard curve from a mixture of proteins with known amounts that have different
sizes and concentration [212].
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Additionally, the majority of these methods are already implemented in several tools available
for proteomics analysis, therefore, it is possible to combine both relative and absolute quanti‐
fications in a simple way, as in the case of the emPAI that is implemented in the MASCOT
server, one of the most used servers in proteomics [214].
A brief presentation of the most used methods for label-free absolute quantification focused
on the major differences between them, and some reports using these methods into the
neuroproteomics field are presented below.
3.4.1. Spectral counting-based methods
Exponentially Modified Protein Abundance Index (emPAI): Mathias Mann's group present‐
ed what would be the first method for absolute quantification by proving that a transformation
of the PAI values (described above) could be in fact associated with the absolute amount of a
given protein [213]. In this study, the authors showed that the PAI values have a linear relation
with the logarithm of protein concentration, therefore the absolute quantification of a given
protein can be obtained by the exponentially modified PAI (emPAI), which is equal to the
following equation 10PAI-1.
Absolute Protein Expression (APEX): In theory, the APEX method is similar to the previously
proposed emPAI method since it is based on the number of peptides identified normalized for
the theoretical number. However, instead of considering the redundant peptides, it relies only
in the unique peptides. And furthermore, which is also its major strength, this method uses
machine learning to calculate the number of theoretical peptides than can be identified in the
particular experiment. To achieve the probable number of peptides, the theoretical number of
peptides is normalized for a correction factor specific for the experimental settings [212, 214].
3.4.2. Intensity based methods
One of the disadvantages of spectral counting based methods already observed for relative
quantification is the fact that in these methods the saturation is easily reached, therefore, failing
in accurately quantifying proteins present at higher levels. On the other hand, as those methods
rely on the MS/MS spectra identification, they are also biased to the most intense proteins,
therefore, spectral counting-based methods are only accurate within a reduced dynamic range.
Furthermore, they also present a large variability between replicates. Similar to what is
observed for relative quantification with the use of MS1 intensity-based methods these
limitations are overcome.
Peak intensity-based absolute quantification method (iBAQ): In this method, the amount of
a given protein is calculated by the sum of the peak intensities of all peptides matching to it,
divided by the number of theoretically observable peptides [215].
LC-MSE: Silva and colleagues reported in 2006 [177] for the first time the relationship between
MS signal response and protein concentration. In this work, the authors discovered that the
average of the three most intense peptides is highly correlated to the effective amount of a
protein in a sample. In this study the authors spiked the samples with a known amount of a
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mixture of proteins (internal standards). The internal standards were then used to calculate a
universal signal response factor (which was shown to be the same for all the tested proteins)
that correlates the intensity calculated with the amount of the proteins, and is then used to
obtain the quantification for the unknown proteins.
Three most intense peptides peak area (T3PQ): The T3PQ method is an adaptation of the
method previously used in LC-MSE [177] for IDA methods [157]. The principle of this approach
relies on the evidence that for each protein (independent on its size) identified by a set of
peptides, the average of the three most efficiently ionized peptides (those with the highest MS
signals) directly correlated with the amount of the corresponding protein. This method proved
to be more accurate and reproducible than the methods already used (in particular, when
compared with the spectral counting methods) [157].
Absolute quantification methods have been used mainly in studies focusing on the under‐
standing of complexes stoichiometry, and not in large screenings that are the most frequent
assays in the neuroproteomics field. Therefore, there are only few reports using label-free-
based absolute quantification, particularly in neuroproteomics, and those are mainly associ‐
ated with the iBAQ method. One of the more interesting reports where iBAQ was used is
perhaps the work regarding the characterization of the isolated synaptic boutons that culmi‐
nate with the establishment of the amounts of the proteins that compose those vesicles [218].
iBAQ was also used to obtain a comprehensive characterization of the protein abundance in
several organs, such as the brain [158], and in some experiments that focus on the determina‐
tion of the amount of enriched proteins in tissue-specific (hair bundles) [219] and condition-
specific (BACE1 knockouts) [220] proteomes.
4. Multiple reaction monitoring
Multiple reaction monitoring (MRM) is a highly selective scan mode in MS that has been
extensively used for the last 30 years for absolute quantification of small molecules [221].
Similarly, the knowledge acquired in small molecules targeted quantification has been
transposed for targeted quantification of peptides and proteins where several reviews can be
found in the literature [222–224]. Shotgun proteomics MS-based studies retrieve the identifi‐
cation of thousands of proteins in a single analysis, plus the relative quantification by label-
free [225, 226] or isotopic labeled strategies [227, 228]. However, in these global profiling
methods, low-abundance peptides may be difficult to be detected, generating “missing data”
and low precision problems that can impair statistical analyses [229, 230]. Consequently, the
untargeted approach has been widely used, for instance, in clinical studies of biomarker
discovery to find new candidates and, the MRM targeted MS-based approach has been used
in the verification/validation phase, overcoming many of the difficulties associated with
antibody-based protein quantification [231, 232].
Developing and validating MRM-MS assays is a laborious process, but once constructed, it
can be used for accurate and precise quantification of one or several proteins on a large scale
and across laboratories [233]. The high selectivity of MRM scan mode is achieved using, most
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predominantly, triple-quadrupole mass spectrometers. Quadrupoles are known as “mass
filters” where in a first stage (Q1), the mass/charge ratio (m/z) of the intact peptide (precursor
ion) is selected, fragmented in the collision cell (q2), and in a second stage (Q3) a specific
fragment of the precursor is selected, generating the selected reaction monitoring experiment
(SRM) with one transition (precursor/ fragment), or if several fragments are being monitored,
an MRM experiment with several transitions (Figure 5A) [234].
A-True MRM
B-High Resolution MRM
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Figure 5. Schematic representation of the (A) MRM scan mode performed in a triple-quadrupole instrument and the
(B) high-resolution multiple reaction monitoring (HR-MRM) scan mode performed in a QqTOF system. In classical
MRM scan mode, the first quadrupole (Q1) selects the m/z of the precursor that will be fragmented in the collision cell
(q2) and one of the resulted fragments is then selected by the third quadrupole (Q3) towards the detector. The two
stages of mass filters (Q1 and Q3) represent a transition and more than one can be monitored in a single run. HR-MRM
works similarly at the first stage (Q1) but after fragmentation, all the fragments are scanned by the TOF mass analyzer
instead of selecting only one each time that the precursor is fragmented. This will generate a high-resolution mass frag‐
mentation spectrum where extracted ion chromatograms for each fragment can be obtained by the use of specific soft‐
wares.
The peptide sequences to be monitored must be carefully selected as they have to be unique
for a given protein, where peptides with less than 8 residues and those susceptible to undergo
modifications during sample processing (methionine oxidation, cysteine alkylation) must be
avoided. Additionally, for protein isoforms or PTM’s quantification, specific peptides should
be selected for accurate measurements. [229, 235, 236]. The combination of LC separation
followed by the MRM acquisition (2 m/z filters) results in high precision, sensitivity, and high
selective measurements for the selected peptides and, consequently, for the protein [229]. The
best candidate peptide(s) to be monitored for the quantification can be selected based on
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prediction tools (in silico) or on experimental evidences [236]. Selection based on empirical
data involves previous LC–MS/MS experiments from the biological sample to obtain prelimi‐
nary information on the peptide characteristics such as ionization and fragmentation. After
the selection of the peptides (precursors) and their specific fragments, MRM transitions are
evaluated by re-analyzing the sample to help in the selection of the most selective and sensitive
for each peptide of interest [237]. In order to avoid long optimization and multiple rounds of
analyses, there are online repositories such as PeptideAtlas, the Global Proteome Machine
Database, and Pride, which contain peptide sequences and empirical MS spectra to support
MRM designing without the need of preliminary sample processing and analysis [229]. Even
for proteins not found in the database, there are several in silico bioinformatic tools that select
high-responding peptides from candidate proteins, such as ESP preditor [238], PeptideSieve
[239], PepFly [240], MIDAS [241], among others. TIQAM is another interesting software tool
that selects the proteotypic peptides based on the in silico prediction and integrates that
information with the PeptideAtlas repository or other sources to generate the list of transitions
based on the validated fragmentation spectrum [242].
The number of proteins monitored by an MRM experiment is usually low and the duty cycle
(the time for the instrument to cycle through separation and detection of each transition) will
depend on the number of peptides per protein and the number of transitions per peptide. To
overcome the limited number of proteins monitored in an MRM experiment, a timed acquis‐
ition mode, termed scheduled MRM (sMRM) analysis was developed where transitions are
acquired only during a defined elution time window [235]. Consequently, thousands of
transitions can be monitored, allowing the quantification of hundreds of proteins in a single
run. Colangelo and collaborators developed a pipeline for large scale (>1000 transitions/run),
label-free LC-MRM assays for the quantification of 112 rat brain synaptic proteins [243]. The
workflow began with data-dependent acquisition using 5600 Triple TOF to identify the
sequences of the peptides present in the biological sample of interest. The peptide library
information was then converted into thousands of MRM transitions that were easily trans‐
posed to the 5500 QTRAP (demonstrating the consistency of the fragmentation patterns
between the instruments) to be acquired using the sMRM methods. To address the very short
dwell times due to the high number of transitions, they presented an improvement in the
sMRM methods' sensitivity and robustness using an intelligence-based MRM acquisition
(termed extended or xMRM). Firstly, variable acquisition windows throughout the run can be
used and secondly, a “triggered xMRM”, where the secondary MRM transition for each
peptide was only monitored if the primary MRM exceeded a given threshold. The xMRM
enabled the reduction of the number of transitions to be monitored at a given time leading to
an increase of 63–68% in the dwell times for peptides and, consequently, an increase in the
sensitivity for the limiting peptide concentrations.
Although MRM is considered to be a very high selective scan mode, the possibility to have
non-desired peptides with isobaric or very similar m/z values can increase with sample
complexity [244]. The consequence of a non-selective method is the overestimation in concen‐
tration determination of the targeted peptide. Therefore, the use of HR-MRM can increase the
method selectivity and consequently improve the accuracy of the quantification. The scan
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mode works as described in the first stage (Q1) and in fragmentation (Q2) for triple quadru‐
poles with the difference in the last stage, where rather than focusing on a single ion fragment
in Q3, fragment ions of all masses are scanned by a TOF analyzer generating high-resolution
MS/MS spectra (Figure 5B). Thus, fragment ions can be extracted from the high-resolution MS/
MS spectra of the targeted peptides to generate extracted ion chromatograms (XICs) of high
resolution [245]. Tong and collaborators performed a targeted HR-MRM analysis for the
quantification of 47 tear proteins using the Triple-TOF mass spectrometer (QqTOF) with good
reproducibility (CV<5%) [245]. In addition to the improvement in selectivity, the multiple steps
for the selection of the best transitions are not required as in triple-quadrupole instruments.
4.1. Absolute quantification of proteins by MRM
Beyond protein identification and relative quantification by MS, absolute quantification of
proteins in biological samples has also been performed using synthetic unlabeled and/or
labeled peptides [12]. Absolute protein quantification has been generally performed based on
the principle of the stable-isotope dilution (SID) where stable isotope-labeled synthetic
analogous are spiked into the samples to extrapolate protein amounts present in a sample.
Gerber and collaborators termed this approach as the AQUA methodology, where the best
candidate peptides for the quantification of a given protein are synthesized with at least one
residue replaced by stable isotopes, resulting in a very similar endogenous peptide (called
AQUA peptides) but with a sufficient m/z difference so that they can be distinguished by MRM
[246]. Protein quantification is performed by spiking the sample with a known amount of the
AQUA peptide and the peak areas ratio of the unlabeled/labeled peptides are used to deter‐
mine the expression levels of the protein of interest. On the other hand, Barnidge and collab‐
orators performed a study to compare protein quantification using two different methods, one
based on the AQUA approach and the other on an external calibration curve created from
successive dilutions of the synthetic unlabeled peptide [247]. Quantification based on the
external calibration curve resulted in better precision and accuracy values than quantification
based on the sample spiking of the analogous labeled synthetic peptide. In this study, the
external calibration curve was able to accurately determine the peptide concentration however,
for more complex samples, the matrix effect should be evaluated so that method accuracy is
not compromised. The ideal approach for accurate and precise peptide quantification would
be the use of external calibration curves prepared in the representative matrix by spiking the
unlabeled synthetic peptide at various concentrations and a constant amount of the analogous
stable isotope synthetic (SIS) peptide as internal standard. However, proteins or peptides of
interest are usually present in the representative matrix that impairs the accuracy and precision
of the quantification method if the calibration curves are performed by spiking the synthetic
unlabeled peptide into the matrix. For that reason, Campbell and collaborators proposed an
alternative approach called the reverse curve method where varying amounts of the labeled
peptide are spiked in the representative matrix to create the calibration curve [248]. In this
work, seven apolipoproteins were quantified in human plasma using the three approaches: a)
spiking the sample with a known amount of the analogous synthetic-labeled peptide (AQUA
approach); b) spiking the representative matrix with different amounts of the unlabeled
synthetic peptide and a constant amount of the labeled peptide to create the “classical”
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calibration curve; and c) spiking the representative matrix with varying amounts of the labeled
synthetic peptide to create the curve and a constant amount of the unlabeled peptide to work
as internal standard (reverse calibration curve). For both cases using external curves, some
corrections are required due to the endogenous peptide already present in the sample. The
correction for the classical calibration curve is performed by subtracting the y-interception of
the curve to the determined concentration of the endogenous peptide in the sample. For the
reverse curve the correction factor corresponds to an increase of each curve point by an amount
proportional to the ratio of the amounts of endogenous unlabeled peptide to the spiked
synthetic unlabeled peptide [29]. The AQUA approach revealed to be inaccurate for endoge‐
nous peptide quantification below and above the concentration of the IS spiked into the sample.
As expected, this result demonstrates that accurate peptide quantification in samples can only
be achieved if the spiked IS amount into the sample is close to the concentration of the
endogenous unlabeled peptide. The reverse curve has the advantage of allowing the determi‐
nation of the limits of detection and quantification (LOD and LOQ) once the representative
matrix does not contain the synthetic-labeled peptide. In addition, the quantification using the
reverse curve revealed to be the most accurate and precise between the three methods, thus
this approach can be used with confidence to quantify endogenous peptides/proteins already
present in the surrogate matrix.
Absolute quantification by MRM applied to neuroproteomics was first described by Desiderio
and collaborators to quantify picomole amounts of the endogenous methionine-enkephalin
(ME) in the human pituitary by comparing the response of the endogenous ME to one of the
deuterated ME internal standard (d5-ME) [249]. More recently, Kheterpal and collaborators
determined the concentration of MIF-1 (neuropeptide) in different regions of mouse brain by
using a calibration curve prepared by successive dilutions of the unlabeled synthetic peptide
in the absence of matrix [250].
There are several studies in Alzheimer’s disease that involve protein/peptide quantification
by MRM [251–253]. Lame and collaborators developed a UPLC-MRM method to accurately
quantify Aβ1-38, Aβ1-40, and Aβ1-42 in human cerebrospinal fluid that can play a crucial role in
understanding disease progression and intervention [254]. The quantification was performed
using calibration curves prepared with various concentrations of the synthetic peptides spiked
with constant amounts of analogous 15N-labeled internal standards in an artificial CSF matrix.
Also, Wildsmith and collaborators described the development of an MRM assay for the
absolute quantification of 39 peptides corresponding to 30 proteins to confirm previous
findings for a subset of markers for Alzheimer’s disease [255].
Another approach that, in combination with MRM, allows absolute quantification based on
the isotope-dilution mass spectrometry or AQUA methodology is peptide labeling with non-
isobaric tags reagents, the mTRAQ reagents. Originally, mTRAQ labels appeared in two
versions, the lighter version (lower in mass than the iTRAQ labels by 4 Da) and the heavy
version that is identical to the iTRAQ 117 label resulting in a light version (Δ0) with a monoi‐
sotopic mass of 141 Da and a heavy version (Δ4) of 145 Da. Furthermore, a new label version
(Δ8) is now available called triplex mTRAQ reagents. These have been used mostly for relative
quantification but DeSouza and collaborators described a method for absolute quantification
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of proteins using the duplex version of mTRAQ reagent. The procedure consisted of labeling
known amounts of the synthetic peptide used for protein quantification with one of the two
versions while, the opposite version was used to tag the endogenous peptides that needed to
be quantified [256]. At the end, these two fractions were mixed at a known amount and the
resulting mixture was analyzed by unique MRM transitions for each version of the labeled
peptide resultant from the different masses of the tags. The areas that resulted from each MRM
transition were then used to determine the unknown concentration of the peptide in the
digested sample and, consequently, the concentration of the protein of interest.
Apart from the AQUA quantification strategy, standard peptides are usually spiked at late
stages of sample processing; they are poorly compatible with sample pre-fractionation; and
the digestion efficiency cannot be fully determined leading to an inaccurate quantification
[257]. To address these issues, other types of standards were developed known as artificial
concatamers of proteotypic peptides (called QconCAT) and are generally added into the
sample just before protein digestion [258]. Concatamers are artificial protein constructs that
include multiple trypsin-cleavable proteotypic peptides isotopically labeled. The isotope-
labeled peptides are released during protein digestion and will be used as standards for the
absolute target protein quantification. The QconCAT methodology possesses the main
advantage of facilitating multiplex protein quantification where typically 10–30 target analyte
proteins are encoded in each QconCAT at a level of two quantotypic peptides per protein [259].
Chen and collaborators stated that a reliable quantitative approach of clusterin in brain was
needed to clarify its role in Alzheimer’s disease. Consequently, they developed a stable
isotope-labeled concatenated peptide (QconCAT) for the quantification of clusterin in human
postmortem frontal and temporal cortex [260]. Later, they applied this approach for other
protein quantifications also related to AD. At this time, a multiplexed QconCAT was designed
for quantification of various isoforms of amyloid precursor protein (APP). Since common
tryptic peptides between all isoforms of APP were concatenated with unique tryptic peptides
for specific APP isoforms, this QconCAT-MRM method allowed the clear quantification of the
total APP and each protein isoform [261].
Even with the advantage of multiplexing absolute quantification, the assessment of the
digestion efficiency remains undetermined once QconCAT are usually digested at high rates,
not giving the true tryptic digestion efficiencies for each protein [258]. By using the isotope-
labeled equivalent of the full-length target protein, the “ideal” internal standards can be added
at the very beginning of sample processing, allowing the determination of the recoveries after
pre-fractionation steps and the assessment of the digestion efficiencies, which is called the
“Protein Standard Absolute Quantification” (PSAQ). A comparative study between AQUA,
QconCAT, and PSAQ was performed for the quantification of Staphylococcus aureus superan‐
tigenic toxins in water and urine samples where the PSAQ strategy revealed to be more
accurate than the two other methods [262]. PSAQ also revealed to be advantageous for the
absolute quantification of membrane proteins that are more prone to errors on concentration
determination due to protein enrichment steps usually required and incomplete digestion
[263]. In this study, accurate quantification of 7 membrane proteins was achieved using as
internal standards the analogous 15N-labeled full-length proteins added at an initial stage of
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sample processing. There are other quantification approaches based on the addiction of full-
length labeled proteins internal standards for protein quantification such as FlexiQuant [264],
PrEST [265], and Absolute SILAC [266].
Although, some of the approaches presented have few publications for absolute protein
quantification by MRM they can be of interest for the neuroproteomics field to confirm
previous findings or to find new targets with more accurate data.
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